NCT06512493 South East (Zuid Oost) Netherlands Heart Registry
| NCT ID | NCT06512493 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Radboud University Medical Center |
| Condition | Coronary Artery Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 99,999 participants |
| Start Date | 2020-11-01 |
| Primary Completion | 2050-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 99,999 participants in total. It began in 2020-11-01 with a primary completion date of 2050-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Rationale: Patients undergoing percutaneous coronary intervention (PCI) for chronic coronary syndrome (CCS) or acute coronary syndrome (ACS) have a residual risk of ischemic events after PCI due to the progression of atherosclerosis in and outside the stented segments. The residual risk is affected by thrombotic, lipid, inflammation and diabetic risk factors. Secondary prevention after PCI is therefore of major importance to reduce complications and improve the patients' prognosis. Objective: To provide an extensive overview on the quality of secondary prevention and personalized medicine, a consortium in the South East Netherlands has created a PCI registry, the "Zuid Oost Nederland Hart Registratie" (ZON-HR).
Eligibility Criteria
No in- or exclusion criteria are applied to gain 100% registration in order to prevent bias.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06512493 clinical trial?
This trial is open to participants of all sexes, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06512493 currently recruiting?
Yes, NCT06512493 is actively recruiting participants. Contact the research team at robertjan.vangeuns@radboudumc.nl for enrollment information.
Where is the NCT06512493 trial being conducted?
This trial is being conducted at Heerlen, Netherlands, Maastricht, Netherlands, Venlo, Netherlands, Nijmegen, Netherlands.
Who is sponsoring the NCT06512493 clinical trial?
NCT06512493 is sponsored by Radboud University Medical Center. The trial plans to enroll 99,999 participants.